Biological Therapy for Asthma
Downloads
Asthma is a heterogeneous chronic inflammatory disease in the respiratory tract that leads to recurrent episodic symptoms. Study about the mechanism of pathophysiology and immunology which stimulates chronic inflammation in asthma has been greatly developed. The understanding of inflammation mediator that is predominant on various asthma phenotypes could be useful for development of diagnosis and targeted therapy. Standard asthma therapy administered through the airway has limited effects only in the airway. The knowledge of molecular pathophysiology and immunology of this disease developed interest of the drugs that perform proximally from inflammation process in the airway, in this case is biological therapy. Several biological therapies have been investigated for its efficacy on human, including Anti IgE (Omalizumab), Anti Interleukin-5 (Mepolizumab, Reslizumab, Benralizumab), Anti Interleukin-4/Interleukin-13 (Dupilumab), and Anti Interleukin-17 (Secukinumab and Brodalumab).
Rogliani P, Calzetta L, Matera MG, et al. Severe Asthma and Biological Therapy: When, Which, and for Whom. Pulm Ther 2020; 6: 47–66.
Mangunrejo H, Widjaja A, Kusumo D, et al. Asma: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia, 2004.
McGregor MC, Krings JG, Nair P, et al. Role of Biologics in Asthma. Am J Respir Crit Care Med 2019; 199: 433–445.
Viswanathan RK, Busse WW. Biologic Therapy and Asthma. Semin Respir Crit Care Med 2018; 39: 100–114.
Corren J. Inflammatory Disorders Associated with Allergy: Overview of Immunopathogenesis and Implications for Treatment. Immunol Allergy Clin 2017; 37: 233–246.
Wenzel SE. Asthma Phenotypes: The Evolution from Clinical to Molecular Approaches. Nat Med 2012; 18: 716–725.
Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that Severe Asthma can be Divided Pathologically into Two Inflammatory Subtypes with
Distinct Physiologic and Clinical Characteristics. Am J Respir Crit Care Med 1999; 160: 1001–1008.
Busse W, Corren J, Lanier BQ, et al. Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma. J Allergy Clin Immunol 2001; 108: 184–190.
Borish L. The Immunology of Asthma: Asthma Phenotypes and Their Implications for Personalized Treatment. Ann Allergy, Asthma Immunol Off Publ Am Coll Allergy, Asthma, Immunol 2016; 117: 108–114.
Asthma GI for. Global Strategy for Asthma Management and Prevention. Wisconsin, http://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf (2019).
Fajt ML, Wenzel SE. Biologic Therapy in Asthma: Entering the New Age of Personalized Medicine. J Asthma 2014; 51: 669–676.
Pepper AN, Renz H, Casale TB, et al. Biologic
Therapy and Novel Molecular Targets of Severe Asthma. J Allergy Clin Immunol Pract 2017; 5: 909–916.
Djukanović R, Wilson SJ, Kraft M, et al. Effects of Treatment with Anti-Immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. Am J Respir Crit Care Med 2004; 170: 583–593.
Hoshino M, Ohtawa J. Effects of Adding Omalizumab, An Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma. Respiration 2012; 83: 520–528.
McCracken JL, Tripple JW, Calhoun WJ. Biologic Therapy in the Management of Asthma. Curr Opin Allergy Clin Immunol 2016; 16: 375–382.
Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. N Engl J Med 2009; 360: 985–993.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (